Premium
O1‐04‐02: A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease
Author(s) -
Quinn Joseph F.,
Raman Rema,
Thomas Ronald G.,
Ernstrom Karin,
YurkoMauro Karin,
Nelson Edward B.,
Shinto Lynne,
Nair Anil K.,
Aisen Paul
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.05.215
Subject(s) - medicine , placebo , dementia , clinical trial , population , docosahexaenoic acid , disease , clinical dementia rating , pediatrics , fatty acid , polyunsaturated fatty acid , biology , pathology , biochemistry , alternative medicine , environmental health
p Conclusions: A trial of DHA supplementation for mild to moderate AD will be completed in May 2009. Recruitment was completed ahead of schedule. The criteria for baseline dietary DHA consumption yielded a baseline plasma DHA level which will permit significant increases with supplementation. The primary analysis of the efficacy (ie, rate of change on ADAS-cog and CDR-SOB) and safety of DHA supplementation in patients with mild to moderate AD will be presented.